Estrogen receptor (ER) β agonists have been demonstrated to possess anti-inflammatory properties in inflammatory disease models. The objective of this study was to determine whether ERβ agonists affect in vitro and in vivo preclinical models of asthma. mRNA expression assays were validated in human and rodent tissue panels. These assays were then used to measure expression in human cells and our characterized rat model of allergic asthma. ERB-041 [7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol], an ERβ agonist, was profiled on cytokine release from interleukin-1β-stimulated human airway smooth muscle (HASM) cells and in the rodent asthma model. Although ERβ expression was demonstrated at the gene and protein level in HASM cells, the agonist failed to have an impact on the inflammatory response. Similarly, in vivo, we observed temporal modulation of ERβ expression after antigen challenge. However, the agonist failed to have an impact on the model endpoints such as airway inflammation, even though plasma levels reflected linear compound exposure and was associated with an increase in receptor activation after drug administration. In these modeling systems of airway inflammation, an ERβ agonist was ineffective. Although ERβ agonists are anti-inflammatory in certain models, this novel study would suggest that they would not be clinically useful in the treatment of asthma.

Title

J Pharmacol Exp Ther JPET 326:83–88, 2008

Publisher

--

Publisher Country

Palestine

Publication Type

Both (Printed and Online)

Volume

--

Year

2008

Pages

--